These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Statins and the neuromuscular system: a neurologist's perspective. Argov Z Eur J Neurol; 2015 Jan; 22(1):31-6. PubMed ID: 25495398 [TBL] [Abstract][Full Text] [Related]
29. How do you treat patients with myalgia who take statins? Siddiqi SA; Thompson PD Curr Atheroscler Rep; 2009 Jan; 11(1):9-14. PubMed ID: 19080722 [TBL] [Abstract][Full Text] [Related]
30. [Autoimmune myopathy associated with statin use]. Ljøstad U; Mygland Å Tidsskr Nor Laegeforen; 2016 Sep; 136(16):1360-2. PubMed ID: 27637055 [TBL] [Abstract][Full Text] [Related]
31. Statin myotoxicity: a review of genetic susceptibility factors. Needham M; Mastaglia FL Neuromuscul Disord; 2014 Jan; 24(1):4-15. PubMed ID: 24176465 [TBL] [Abstract][Full Text] [Related]
32. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Harper CR; Jacobson TA Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856 [TBL] [Abstract][Full Text] [Related]
33. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Gillett RC; Norrell A Am Fam Physician; 2011 Mar; 83(6):711-6. PubMed ID: 21404982 [TBL] [Abstract][Full Text] [Related]
34. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Kostapanos MS; Milionis HJ; Elisaf MS Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931 [TBL] [Abstract][Full Text] [Related]
35. Selenoprotein synthesis and side-effects of statins. Moosmann B; Behl C Lancet; 2004 Mar; 363(9412):892-4. PubMed ID: 15031036 [TBL] [Abstract][Full Text] [Related]
36. Statin-induced necrotizing autoimmune myopathy (SINAM): case report and review of the literature. Cornelis L; Duyck J; Dedeurwaerdere F; De Schoenmakere G; Malfait T Acta Clin Belg; 2023 Aug; 78(4):336-341. PubMed ID: 36511106 [TBL] [Abstract][Full Text] [Related]
37. HMG-CoA reductase inhibitors and myotoxicity. Ucar M; Mjörndal T; Dahlqvist R Drug Saf; 2000 Jun; 22(6):441-57. PubMed ID: 10877038 [TBL] [Abstract][Full Text] [Related]
39. Statin safety: an appraisal from the adverse event reporting system. Davidson MH; Clark JA; Glass LM; Kanumalla A Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327 [TBL] [Abstract][Full Text] [Related]
40. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. García Rodríguez LA; Herings R; Johansson S Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]